NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Portfolio Pulse from
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Intellia Therapeutics (NTLA) alleging the company made false or misleading statements about its drug NTLA-3001's development and viability between July 30, 2024 and January 8, 2025. The lawsuit claims Intellia misrepresented the potential of viral-based editing programs and the drug's research and development capabilities.
March 26, 2025 | 11:15 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The class action lawsuit could negatively impact Intellia's stock price by raising concerns about the company's transparency and drug development claims.
The lawsuit alleges serious misrepresentations about NTLA-3001's development, which could damage investor confidence, potentially leading to stock price decline.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100